Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13

Science

Volumn 265, Issue 5181, 1994, Pages 2088-2090

  Wooster, Richard ^a   Neuhausen, Susan L ^b   Mangion, Jonathan ^a   Quirk, Yvette ^a   Ford, Deborah ^a   Collins, Nadine ^a   Nguyen, Kim ^b   Seal, Sheila ^a   Tran, Thao ^b   Averill, Diane ^a   Fields, Patty ^b   Marshall, Gill ^a   Narod, Steven ^c   Lenoir, Gilbert M ^d   Lynch, Henry ^e   Feunteun, Jean ^f   Devilee, Peter ^g   Cornelisse, Cees J ^g   Menko, Fred H ^h   Daly, Peter A ⁱ   Ormiston, Wilma ⁱ   McManus, Ross ⁱ   Pye, Carole ^j   Lewis, Cathryn M ^b   Cannon Albright, Lisa A ^b   Peto, Julian ^a   Ponder, Bruce A J ^j   Skolnick, Mark H ^b   Easton, Douglas F ^a   Goldgar, David E ^b   Stratton, Michael R ^a   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF UTAH   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^e CREIGHTON UNIVERSITY   (United States)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g LEIDEN UNIVERSITY   (Netherlands)

^h VU UNIVERSITY AMSTERDAM   (Netherlands)

ⁱ TRINITY COLLEGE DUBLIN   (Ireland)

^j UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CHROMOSOMAL LOCALIZATION; CHROMOSOME 13Q; CONTROLLED STUDY; FEMALE; GENE LOCATION; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0028006563     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.8091231     Document Type: Article

References (32)

1. J. M. Hall et al., Science 250, 1684 (1990); S. A. Narod et al., Lancet 338, 82 (1991).
2. J. M. Hall et al., Science 250, 1684 (1990); S. A. Narod et al., Lancet 338, 82 (1991).
3. D. F. Easton, D. T. Bishop, D. Ford, G. P. Crockford, and the Breast Cancer Linkage Consortium, Am. J. Hum. Genet. 52, 678 (1993); M. R. Stratton et al., Nat. Genet. 7, 103 (1994).
4. D. F. Easton, D. T. Bishop, D. Ford, G. P. Crockford, and the Breast Cancer Linkage Consortium, Am. J. Hum. Genet. 52, 678 (1993); M. R. Stratton et al., Nat. Genet. 7, 103 (1994).
5. J. M. Birch et al., Cancer Res. 54, 1298 (1994); D. Malkin et al., Science 250, 1233 (1990); S. Srivastava, Z. Zou, K. Pirollo, W. Blattner, E. H. Chang, Nature 348, 747 (1990).
6. J. M. Birch et al., Cancer Res. 54, 1298 (1994); D. Malkin et al., Science 250, 1233 (1990); S. Srivastava, Z. Zou, K. Pirollo, W. Blattner, E. H. Chang, Nature 348, 747 (1990).
7. J. M. Birch et al., Cancer Res. 54, 1298 (1994); D. Malkin et al., Science 250, 1233 (1990); S. Srivastava, Z. Zou, K. Pirollo, W. Blattner, E. H. Chang, Nature 348, 747 (1990).
8. R. Wooster et al., Nat. Genet. 2, 132 (1992); J.-M. Lobaccaro et al., ibid. 5, 109 (1993).
9. R. Wooster et al., Nat. Genet. 2, 132 (1992); J.-M. Lobaccaro et al., ibid. 5, 109 (1993).
10. M. Swift, D. Morrell, R. Massey, C. L. Chase, N. Engl. J. Med. 325, 1831 (1991).
11. J. Prosser et al., Br. J. Cancer 63, 181 (1991); W. Warren et al., Oncogene 7, 1043 (1992); R. Wooster et al., Hum. Genet. 92, 91 (1993).
12. J. Prosser et al., Br. J. Cancer 63, 181 (1991); W. Warren et al., Oncogene 7, 1043 (1992); R. Wooster et al., Hum. Genet. 92, 91 (1993).
13. J. Prosser et al., Br. J. Cancer 63, 181 (1991); W. Warren et al., Oncogene 7, 1043 (1992); R. Wooster et al., Hum. Genet. 92, 91 (1993).
14. J. Weissenbach et al., Nature 359, 794 (1992); G. Gyapay et al., Nat. Genet. 7, 246 (1994).
15. J. Weissenbach et al., Nature 359, 794 (1992); G. Gyapay et al., Nat. Genet. 7, 246 (1994).
16. Genotyping was performed independently at the Institute of Cancer Research [R. Wooster et al., Nat. Genet. 6, 152 (1994)] and the University of Utah [L. A. Cannon-Albright et al., Science 258, 1148 (1994)].
17. Genotyping was performed independently at the Institute of Cancer Research [R. Wooster et al., Nat. Genet. 6, 152 (1994)] and the University of Utah [L. A. Cannon-Albright et al., Science 258, 1148 (1994)].
18. Lod scores were computed with the FASTLINK version of the LINKAGE program [G. M. Lathrop, J. M. Lalouel, C. Julier, J. Ott, Proc. Natl. Acad. Sci. U.S.A. 81, 3443 (1984); R. W. Cottingham Jr., R. M. Idury, A. A. Schaffer, Am. J. Hum. Genet. 53, 252 (1993)], using a model for familial breast cancer derived from the segregation analysis of the Cancer and Steroid Hormone Study (CASH). Under this model, susceptibility to breast cancer is conferred by an autosomal dominant gene with population frequency 0.0033, and the risk of breast cancer by age 70 in carriers is 0.67 compared to 0.05 in noncarriers. Penetrances for ovarian cancer in carriers of the breast cancer susceptibility gene were derived from E. B. Claus, J. M. Schildkraut, W. D. Thompson, and N. J. Risch [Am. J. Hum. Genet. 53, A787 (1993)], which estimated a cumulative frequency of 10% by age 60. The effects of age were incorporated into the analyses as in (2). Male breast cancer cases were as to the same liability classes as female breast cancer cases diagnosed below age 30. All cancers other than breast and ovarian cancer were ignored in this analysis Allele frequencies were those reported in the Genome Data Base and were based on 56 CEPH (Centre d'Etude du Polymorphisme Humain) chromosomes. Evidence for heterogeneity was evaluated by the admixture model [J. Ott, Analysis of Human Genetic Linkage (Johns Hopkins Univ. Press, Baltimore, 1985). pp. 200-203]. Lod scores for linkage to BRCA1 were computed as in (5).
19. Lod scores were computed with the FASTLINK version of the LINKAGE program [G. M. Lathrop, J. M. Lalouel, C. Julier, J. Ott, Proc. Natl. Acad. Sci. U.S.A. 81, 3443 (1984); R. W. Cottingham Jr., R. M. Idury, A. A. Schaffer, Am. J. Hum. Genet. 53, 252 (1993)], using a model for familial breast cancer derived from the segregation analysis of the Cancer and Steroid Hormone Study (CASH). Under this model, susceptibility to breast cancer is conferred by an autosomal dominant gene with population frequency 0.0033, and the risk of breast cancer by age 70 in carriers is 0.67 compared to 0.05 in noncarriers. Penetrances for ovarian cancer in carriers of the breast cancer susceptibility gene were derived from E. B. Claus, J. M. Schildkraut, W. D. Thompson, and N. J. Risch [Am. J. Hum. Genet. 53, A787 (1993)], which estimated a cumulative frequency of 10% by age 60. The effects of age were incorporated into the analyses as in (2). Male breast cancer cases were as to the same liability classes as female breast cancer cases diagnosed below age 30. All cancers other than breast and ovarian cancer were ignored in this analysis Allele frequencies were those reported in the Genome Data Base and were based on 56 CEPH (Centre d'Etude du Polymorphisme Humain) chromosomes. Evidence for heterogeneity was evaluated by the admixture model [J. Ott, Analysis of Human Genetic Linkage (Johns Hopkins Univ. Press, Baltimore, 1985). pp. 200-203]. Lod scores for linkage to BRCA1 were computed as in (5).
20. Lod scores were computed with the FASTLINK version of the LINKAGE program [G. M. Lathrop, J. M. Lalouel, C. Julier, J. Ott, Proc. Natl. Acad. Sci. U.S.A. 81, 3443 (1984); R. W. Cottingham Jr., R. M. Idury, A. A. Schaffer, Am. J. Hum. Genet. 53, 252 (1993)], using a model for familial breast cancer derived from the segregation analysis of the Cancer and Steroid Hormone Study (CASH). Under this model, susceptibility to breast cancer is conferred by an autosomal dominant gene with population frequency 0.0033, and the risk of breast cancer by age 70 in carriers is 0.67 compared to 0.05 in noncarriers. Penetrances for ovarian cancer in carriers of the breast cancer susceptibility gene were derived from E. B. Claus, J. M. Schildkraut, W. D. Thompson, and N. J. Risch [Am. J. Hum. Genet. 53, A787 (1993)], which estimated a cumulative frequency of 10% by age 60. The effects of age were incorporated into the analyses as in (2). Male breast cancer cases were as to the same liability classes as female breast cancer cases diagnosed below age 30. All cancers other than breast and ovarian cancer were ignored in this analysis Allele frequencies were those reported in the Genome Data Base and were based on 56 CEPH (Centre d'Etude du Polymorphisme Humain) chromosomes. Evidence for heterogeneity was evaluated by the admixture model [J. Ott, Analysis of Human Genetic Linkage (Johns Hopkins Univ. Press, Baltimore, 1985). pp. 200-203]. Lod scores for linkage to BRCA1 were computed as in (5).
21. Lod scores were computed with the FASTLINK version of the LINKAGE program [G. M. Lathrop, J. M. Lalouel, C. Julier, J. Ott, Proc. Natl. Acad. Sci. U.S.A. 81, 3443 (1984); R. W. Cottingham Jr., R. M. Idury, A. A. Schaffer, Am. J. Hum. Genet. 53, 252 (1993)], using a model for familial breast cancer derived from the segregation analysis of the Cancer and Steroid Hormone Study (CASH). Under this model, susceptibility to breast cancer is conferred by an autosomal dominant gene with population frequency 0.0033, and the risk of breast cancer by age 70 in carriers is 0.67 compared to 0.05 in noncarriers. Penetrances for ovarian cancer in carriers of the breast cancer susceptibility gene were derived from E. B. Claus, J. M. Schildkraut, W. D. Thompson, and N. J. Risch [Am. J. Hum. Genet. 53, A787 (1993)], which estimated a cumulative frequency of 10% by age 60. The effects of age were incorporated into the analyses as in (2). Male breast cancer cases were as to the same liability classes as female breast cancer cases diagnosed below age 30. All cancers other than breast and ovarian cancer were ignored in this analysis Allele frequencies were those reported in the Genome Data Base and were based on 56 CEPH (Centre d'Etude du Polymorphisme Humain) chromosomes. Evidence for heterogeneity was evaluated by the admixture model [J. Ott, Analysis of Human Genetic Linkage (Johns Hopkins Univ. Press, Baltimore, 1985). pp. 200-203]. Lod scores for linkage to BRCA1 were computed as in (5).
22. C. Lundberg, L. Skoog, W. K. Cavenee, M. Nordenskjold, Proc. Natl. Acad. Sci. U.S.A. 84, 2372 (1987); P. Devilee, M. van den Brock, N. Kuipers-Dijkshoom, R. Kolluri, P. M. Khan, Genomics 5, 554 (1989); D. Deng et al., Cancer Res. 54, 499 (1994).
23. C. Lundberg, L. Skoog, W. K. Cavenee, M. Nordenskjold, Proc. Natl. Acad. Sci. U.S.A. 84, 2372 (1987); P. Devilee, M. van den Brock, N. Kuipers-Dijkshoom, R. Kolluri, P. M. Khan, Genomics 5, 554 (1989); D. Deng et al., Cancer Res. 54, 499 (1994).
24. C. Lundberg, L. Skoog, W. K. Cavenee, M. Nordenskjold, Proc. Natl. Acad. Sci. U.S.A. 84, 2372 (1987); P. Devilee, M. van den Brock, N. Kuipers-Dijkshoom, R. Kolluri, P. M. Khan, Genomics 5, 554 (1989); D. Deng et al., Cancer Res. 54, 499 (1994).
25. E. Y.-H, P. Lee et al. Science 241, 218 (1988); A. T'Ang, J. M. Varley, S. Chakraborty, A. L. Murphree, Y.-K. T. Fung, ibid. 242, 263 (1988).
26. E. Y.-H, P. Lee et al. Science 241, 218 (1988); A. T'Ang, J. M. Varley, S. Chakraborty, A. L. Murphree, Y.-K. T. Fung, ibid. 242, 263 (1988).
27. J. Toguchida et al., Genomics 17, 535 (1993).
28. O. Rosnet et al., Oncogene 8, 173 (1993).
29. C. J. Kho and H. Zarbl, Proc. Natl. Acad. Sci. U.S.A. 89, 2200 (1992).
30. D. T. Bishop et al., Genet. Epidemiol. 5, 151 (1988).
31. D. F. Easton, D. Ford, D. T. Bishop, and the Breast Cancer Linkage Consortium, unpublished data.
32. All studies were carried out with the full informed consent of the families. We thank the Cancer Research Campaign, the Medical Research Council, the Committee for Clinical Research of the Royal Marsden Hospital, the National Institutes of Health (grants CA-48711, HG-00571, CN-05222, and RR-00064), grant DAMB17-94-J-4260 from the U.S. Army, Myriad Genetics, the European Community Concerted Action on Genetics and Epidemiology of Hereditary Breast Cancer Linkage (PL920890). the Chetwood Aiken fund, and the Ligue Nationale contre le Cancer for their support. We also thank the families for their encouragement and cooperation, the many clinicians who have helped in the identification of cases, in particular the late Dr. E. Gardner, all the members of the International Breast Cancer Linkage Consortium, F. Lennard, M. Ponder, and T. Harrington.